Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. openmedicine

openMedicine

openMedicine

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 openMedicine project word cloud

Explore the words cloud of the openMedicine project. It provides you a very rough idea of what is the project "openMedicine" about.

interoperable    respect    csa    practicability    standards    phc34    regulatory    harmonise    serious    25    efforts    post    abroad    network    message    solved    industry    develops    assure    wp4    conceptual    usa    solutions    cen    description    rules    mapping    validated    framework    idmp    wps    mss    indications    wp1    scenarios    data    lasts    roadmap    dispensed    models    experts    pharmacokinetic    road    ehealth    innovation    hl7    beneficiaries    iso    sdos    explores    mps    epsos    considering    pharmaceutical    practices    recommendations    clinical    risks    economic    link    options    prescribed    f2f    mou    cross    trust    gs1    ms    policy    duty    encountered    concise    meetings    national    safety    attributes    communication    healthcare    ema    wp5    ihtsdo    situation    agencies    core    unambiguous    identification    expanding    substitution    team    professionals    definition    implementations    stage    univocal    mp    transfer    global    meta    therapeutic    pharmacological    health    expert    stakeholders    issue    patients    map    border    vocabulary    acceptance    eprescriptions    workshops    actions    medicinal    investigates    implementability    track    wp3    competent   

Project "openMedicine" data sheet

The following table provides information about the project.

Coordinator		 EMPIRICA GESELLSCHAFT FUR KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG MBH 

Organization address
address: OXFORDSTRASSE 2
city: BONN
postcode: 53111
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Germany [DE]
 Project website http://www.open-medicine.eu
 Total cost 997˙938 €
 EC max contribution 997˙938 € (100%)
 Programme 1. H2020-EU.3.1.5. (Methods and data)
 Code Call H2020-PHC-2014-single-stage
 Funding Scheme CSA
 Starting year 2015
 Duration (year-month-day) from 2015-01-01   to  2016-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EMPIRICA GESELLSCHAFT FUR KOMMUNIKATIONS UND TECHNOLOGIEFORSCHUNG MBH DE (BONN) coordinator 191˙875.00
2    CUSTODIX NV BE (SINT-MARTENS-LATEM) participant 299˙625.00
3    HEALTH PRODUCTS REGULATORY AUTHORITY IE (DUBLIN) participant 110˙625.00
4    HL7 INTERNATIONAL FONDATION BE (BRUSSELS) participant 90˙313.00
5    SIEC BADAWCZA LUKASIEWICZ INSTYTUTLOGISTYKI I MAGAZYNOWANIA PL (POZNAN) participant 87˙625.00
6    REGIONE LOMBARDIA IT (MILANO) participant 80˙625.00
7    AGENCIA ESPANOLA DE MEDICAMENTOS Y PRODUCTOS SANITARIOS ES (MADRID) participant 74˙375.00
8    STICHTING KONINKLIJK NEDERLANDS NORMALISATIE INSTITUUT NL (DELFT) participant 62˙875.00

Map

 Project objective

The CSA will enhance the safety of cross-border healthcare through interoperable ePrescriptions. epSOS solved the message transfer problem, but encountered 2 serious “delivery” problems: the univocal identification of medicinal products (MPs) dispensed abroad, and substitution challenges. Global SDOs (WHO, HL7, IHTSDO, ISO/CEN, GS1), EU regulatory agencies (EMA), MS Competent Authorities, major stakeholders (industry, health professionals, patients) harmonise their related efforts to deliver • common data models - expanding upon epSOS and existing standards (ISO/IDMP) - for prescribed MPs • a common meta-vocabulary for unambiguous definition, description, and identification of MPs • rules to harmonise practices of therapeutic and economic substitution • a roadmap for post-project actions and implementations • policy recommendations for the EU-USA road mapping process (MoU) Work will link to related research & innovation activities of SDOs, epSOS, policy and regulatory processes (eHealth Network), the three other PHC34 projects. WP1 develops a concise conceptual framework, including use case scenarios where the identification of a MP is an issue, including pharmacological and pharmacokinetic attributes, clinical indications and risks. WPs 2 address the identification and description of the pharmaceutical products, considering implementability as essential. WP3 investigates the situation in MSs with respect to substitution, and explores options for substitution. Each track develops a set of concrete solutions and road map recommendations, validated by experts in F2F meetings and workshops in WP4. Fostering exploitation by MS regulatory agencies and communication of results is the duty of WP5. The project involves national competent authorities, SDOs and stakeholders not part of the core team at an early stage to assure the practicability, acceptance and trust in the solutions developed. The CSA lasts 2 years involving 8 beneficiaries and about 25 expert organisations.

 Deliverables

List of deliverables.
D6.1 1st annual report on the activities of the Expert Council Documents, reports 2019-07-23 09:11:13
D2.1 Report on standards based identification and description enabling dispensing equivalent medicinal products Documents, reports 2019-07-23 09:11:14
D1.2 Complementary uses cases Documents, reports 2019-07-23 09:11:14
D1.1 epSOS identification/description problems Documents, reports 2019-07-23 09:11:14
D2.3 openMedicine final identifying and descriptive attributes Documents, reports 2019-07-23 09:11:14
D8.2 openMedicine portal online Websites, patent fillings, videos etc. 2019-07-23 09:11:14
D5.2 openMedicine substitution: options and roadmap Documents, reports 2019-07-23 09:11:13
D5.1 Meeting the substitution challenge: Member State regulations and core cross-border issues Documents, reports 2019-07-23 09:11:13
D7.1 Communication Plan Documents, reports 2019-07-23 09:11:13
D6.2 Report on validation activities Documents, reports 2019-07-23 09:11:13
D1.3 Initial openMedicine infostructure Documents, reports 2019-07-23 09:11:14
D7.2 1st Communication and Liaison Report Documents, reports 2019-07-23 09:11:14
D7.3 2nd Communication and Liaison Report Documents, reports 2019-07-23 09:11:14
D6.4 2nd annual report on the activities of the Expert Council Documents, reports 2019-07-23 09:11:14
D6.3 openMedicine Recommendations and Roadmap for Implementation Documents, reports 2019-07-23 09:11:13
D2.2 Comprehensive set of openMedicine identifying and descriptive attributes of medicinal products and the available standards Documents, reports 2019-07-23 09:11:14

Take a look to the deliverables list in detail:  detailed list of openMedicine deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OPENMEDICINE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OPENMEDICINE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.5.)

EUCANCan (2019)

EUCANCan: a federated network of aligned and interoperable infrastructures for the homogeneous analysis, management and sharing of genomic oncology data for Personalized Medicine.

Read More  

iReceptor Plus (2019)

ARCHITECTURE AND TOOLS FOR THE QUERY OF ANTIBODY AND T-CELL RECEPTOR SEQUENCING DATA REPOSITORIES FOR ENABLING IMPROVED PERSONALIZED MEDICINE AND IMMUNOTHERAPY

Read More  

Instand-NGS4P (2020)

Integrated and standardized NGS workflows for Personalised therapy

Read More